Shares of Illumina, Inc. (NASDAQ:ILMN – Get Rating) have earned an average rating of “Hold” from the twenty-three analysts that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and seven have issued a buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $249.37.
ILMN has been the topic of several research reports. Piper Sandler reissued an “overweight” rating and set a $290.00 price target on shares of Illumina in a research report on Wednesday, February 8th. Argus lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday, January 25th. They noted that the move was a valuation call. Barclays decreased their target price on Illumina from $160.00 to $150.00 and set an “underweight” rating on the stock in a report on Wednesday, February 8th. OTR Global upgraded Illumina from a “mixed” rating to a “positive” rating in a research report on Tuesday, December 20th. Finally, Scotiabank started coverage on Illumina in a report on Wednesday, January 4th. They issued a “sector perform” rating and a $216.00 target price on the stock.
Illumina Stock Down 1.4 %
Shares of NASDAQ ILMN opened at $224.95 on Friday. The stock has a fifty day moving average price of $208.40 and a 200 day moving average price of $208.60. The company has a market cap of $35.54 billion, a P/E ratio of -8.03, a P/E/G ratio of 8.27 and a beta of 1.15. The company has a current ratio of 1.28, a quick ratio of 1.08 and a debt-to-equity ratio of 0.23. Illumina has a 12-month low of $173.45 and a 12-month high of $371.16.
In other Illumina news, SVP Aimee L. Hoyt sold 3,917 shares of the stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $199.06, for a total value of $779,718.02. Following the completion of the sale, the senior vice president now directly owns 2,881 shares in the company, valued at $573,491.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Illumina news, SVP Alexander Aravanis sold 5,398 shares of the business’s stock in a transaction that occurred on Wednesday, February 22nd. The stock was sold at an average price of $201.74, for a total transaction of $1,088,992.52. Following the transaction, the senior vice president now owns 2,922 shares of the company’s stock, valued at approximately $589,484.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Aimee L. Hoyt sold 3,917 shares of Illumina stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $199.06, for a total value of $779,718.02. Following the transaction, the senior vice president now owns 2,881 shares of the company’s stock, valued at approximately $573,491.86. The disclosure for this sale can be found here. Insiders have sold a total of 11,186 shares of company stock valued at $2,255,837 in the last 90 days. 0.13% of the stock is owned by company insiders.
Hedge Funds Weigh In On Illumina
A number of large investors have recently made changes to their positions in the company. Twin Tree Management LP bought a new position in Illumina in the 3rd quarter valued at about $1,147,000. M&G Investment Management Ltd. raised its position in Illumina by 12.3% during the second quarter. M&G Investment Management Ltd. now owns 105,825 shares of the life sciences company’s stock valued at $19,472,000 after purchasing an additional 11,555 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Illumina by 31.5% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 5,437 shares of the life sciences company’s stock valued at $1,002,000 after purchasing an additional 1,302 shares in the last quarter. Alaethes Wealth LLC increased its stake in shares of Illumina by 19.5% in the 2nd quarter. Alaethes Wealth LLC now owns 3,791 shares of the life sciences company’s stock valued at $699,000 after purchasing an additional 619 shares during the last quarter. Finally, Amalgamated Bank lifted its holdings in shares of Illumina by 1.1% in the third quarter. Amalgamated Bank now owns 39,880 shares of the life sciences company’s stock worth $7,609,000 after acquiring an additional 452 shares during the last quarter. Institutional investors own 87.97% of the company’s stock.
Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions.
- Get a free copy of the StockNews.com research report on Illumina (ILMN)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.